Intravenous tranexamic acid vs. sublingual misoprostol in high-risk women for postpartum haemorrhage following cesarean delivery; a randomised clinical trial
BMC Pregnancy and Childbirth · 2023
DOI: 10.1186/s12884-023-05935-5 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift BMC Pregnancy and Childbirth, 2023. Verfasst von Mariam Dawoud und 5 weiteren Autor:innen. Beteiligte Einrichtung: Obstetrics and Gynaecology Department, Faculty of Medicine, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Postpartum Hemorrhage, Tranexamic Acid, Misoprostol. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Centre Egypt.
Abstract (Originalsprache)
Objective
This study compares the effectiveness of administering sublingual misoprostol combined with oxytocin to that of IV tranexamic acid combined with oxytocin to reduce intra and post-operative blood loss in high-risk women for postpartum haemorrhage (PPH) following cesarean section (CS).
Methods
About 315 high-risk pregnant women undergoing CS participated in this trial. They were randomly assigned into three groups; tranexamic group, misoprostol group, and control group, according to the medication given in the operative theatre. All patients received oxytocin intraoperatively. They were assessed regarding intraoperative blood loss, the incidence of PPH, and the reduction in haemoglobin and hematocrit values.
Results
Both tranexamic and misoprostol groups had similar results in reducing intra and post-operative blood loss. However, the reduction in haemoglobin and hematocrit were significantly lower in tranexamic and misoprostol groups compared to the control group (-0.78 ± 0.57 vs. -0.83 ± 0.52 vs. -1.32 ± 0.57 gm/dl, P < 0.001 and − 3.05 ± 1.28 vs. -3.06 ± 1.13 vs. -4.94 ± 1.82%, P < 0.001 respectively). In addition, the estimated blood loss was significantly lower in the tranexamic and misoprostol groups compared to the control group (641.6 ± 271.9 vs. 617.9 ± 207.4 vs. 1002.4 ± 340.7 ml, P < 0.001).
Conclusion
Both tranexamic acid and misoprostol are equally capable of reducing blood loss, but the results were significantly better compared to using oxytocin alone in high-risk patients. Clinical Trial Registration Registered at www.clinicaltrials.govon07/10/2019 with registration number NCT04117243.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Obstetrics and Gynaecology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
- Reproductive Health Research Department, National Research Centre, 33 El-Buhouth St, Dokki, 12622, Cairo, Egypt. doctor_mazen@hotmail.com.
Förderung
- National Research Centre Egypt
Zitieren
APA
Dawoud, M., Al-Husseiny, M., Helal, O., Elsherbini, M., Abdel-Rasheed, M., & Sediek, M. (2023). Intravenous tranexamic acid vs. sublingual misoprostol in high-risk women for postpartum haemorrhage following cesarean delivery; a randomised clinical trial. BMC Pregnancy and Childbirth. https://doi.org/10.1186/s12884-023-05935-5
Vancouver
Dawoud M, Al-Husseiny M, Helal O, Elsherbini M, Abdel-Rasheed M, Sediek M. Intravenous tranexamic acid vs. sublingual misoprostol in high-risk women for postpartum haemorrhage following cesarean delivery; a randomised clinical trial. BMC Pregnancy and Childbirth. 2023. doi:10.1186/s12884-023-05935-5
BibTeX
@article{Dawoud2023,
author = {Dawoud, Mariam and Al-Husseiny, Maha and Helal, Omneya and Elsherbini, Moutaz and Abdel-Rasheed, Mazen and Sediek, Mona},
title = {Intravenous tranexamic acid vs. sublingual misoprostol in high-risk women for postpartum haemorrhage following cesarean delivery; a randomised clinical trial},
journal = {BMC Pregnancy and Childbirth},
year = {2023},
doi = {10.1186/s12884-023-05935-5}
}
EUVIMED